A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Summary

This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.

Timeline

Start

2019-04-30

Primary completion

2024-05-17

Completion

2024-05-17

Outcome

Outcome not reported

Stopped (Business): “Change in corporate strategy”

Drugs

Indications